Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vanda Pharmaceuticals Inc. on February 20, 2020, regarding events occurring on February 18, 2020. The filing addresses significant changes in the company's executive leadership, specifically within the finance department.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation: James P. Kelly resigned as Executive Vice President, Chief Financial Officer, and Treasurer, effective March 15, 2020, to pursue other endeavors.
- Appointment: Kevin Moran was appointed as Vice President, Acting Chief Financial Officer, and Treasurer, effective March 15, 2020.
- Compensation: Mr. Moran's annual base salary is $257,250, with an annual target bonus of 30% of his base salary.
Outlook, Risks, and Management Commentary
The filing notes that Mr. Moran has extensive internal experience, having served as Vice President and Controller since March 2018 and in various finance roles at the company since September 2010. Prior to joining Vanda, he was a Senior Associate at PricewaterhouseCoopers. An indemnification agreement has been executed for Mr. Moran in accordance with Delaware law. No specific guidance, risks, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Confirm the effective date of the CFO transition is March 15, 2020.
- Verify the compensation structure for the new Acting CFO ($257,250 base + 30% target bonus).
- Review the company's subsequent filings for any impact on financial reporting timelines or internal controls due to the leadership change.
- Check for any additional executive departures or appointments not covered in this specific 8-K.